{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T01:14:57Z","timestamp":1648948497425},"reference-count":10,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,24]]},"DOI":"10.1182\/blood.2019002897","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T15:35:35Z","timestamp":1571931335000},"page":"1366-1367","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A sobering \u201ccheck\u201d on immune checkpoint inhibitors"],"prefix":"10.1182","volume":"134","author":[{"given":"Adrienne A.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"issue":"17","key":"2019111521304010300_B1","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood."},{"issue":"11","key":"2019111521304010300_B2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"2019111521304010300_B3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.virol.2012.09.028","article-title":"HTLV-1: persistence and pathogenesis","volume":"435","author":"Cook","year":"2013","journal-title":"Virology"},{"issue":"20","key":"2019111521304010300_B4","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111521304010300_B5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4049\/jimmunol.1701188","article-title":"Unblocking the complexities of tumor-associated regulatory T cells","volume":"200","author":"Chao","year":"2018","journal-title":"J Immunol"},{"issue":"38","key":"2019111521304010300_B6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of response and progression to immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"2019111521304010300_B7","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111521304010300_B8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3502.3502","article-title":"Outcomes of allogeneic hematopoietic stem celltransplantation (HSCT) after treatment withnivolumabforrelapsed\/refractory Hodgkin lymphoma [abstract]","volume":"128","author":"Armand","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2019111521304010300_B9","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2019111521304010300_B10","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/17\/1366\/1502385\/bloodbld2019002897c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/17\/1366\/1502385\/bloodbld2019002897c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:51:09Z","timestamp":1573861869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/17\/1366\/387163\/A-sobering-check-on-immune-checkpoint-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":10,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019002897","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]}}}